$163.39 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
Wall Street brokerages predict that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will post sales of $163.39 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for AMAG Pharmaceuticals’ earnings, with the highest sales estimate coming in at $178.41 million and the lowest estimate coming in at $155.46 million. AMAG Pharmaceuticals posted sales of $151.59 million during the same quarter last year, which would indicate a positive year over year growth rate of 7.8%. The business is scheduled to announce its next quarterly earnings report on Tuesday, February 13th.
According to Zacks, analysts expect that AMAG Pharmaceuticals will report full-year sales of $163.39 million for the current year, with estimates ranging from $607.98 million to $619.76 million. For the next year, analysts expect that the firm will report sales of $526.37 million per share, with estimates ranging from $474.90 million to $653.60 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover AMAG Pharmaceuticals.
A number of research analysts recently commented on the stock. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Wednesday, October 4th. Morgan Stanley started coverage on shares of AMAG Pharmaceuticals in a research report on Friday, September 8th. They set an “overweight” rating and a $26.00 price objective on the stock. Cantor Fitzgerald reiterated a “hold” rating and issued a $21.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. BidaskClub cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, Cowen reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $24.00.
Institutional investors have recently modified their holdings of the company. State of Alaska Department of Revenue lifted its stake in shares of AMAG Pharmaceuticals by 81.3% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 3,081 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in AMAG Pharmaceuticals by 6.6% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after purchasing an additional 510 shares during the last quarter. Hartford Investment Management Co. acquired a new position in AMAG Pharmaceuticals during the 3rd quarter valued at $186,000. Cubist Systematic Strategies LLC acquired a new position in AMAG Pharmaceuticals during the 3rd quarter valued at $197,000. Finally, 361 Capital LLC acquired a new position in AMAG Pharmaceuticals during the 3rd quarter valued at $197,000.
ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/02/163-39-million-in-sales-expected-for-amag-pharmaceuticals-inc-amag-this-quarter.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.